

Type 2 Diabetes – routine OPD management

Key Facts

- Prevalence in Kenya around 3.3%
- Small risk directly from hyperglycaemia (e.g. DKA and HHS)
- Main risk is from associated microvascular and macrovascular disease
- **Lifestyle measures and BP control** are the most important interventions

Screening

- **People with symptoms**
- **Those with risk factors for diabetes:**
 - Obesity: BMI >30, waist circumference >94cm (men); >90cm (Asian men); >80cm (all women)
 - Hypertension or cardiovascular disease
 - Frequent infections, particularly skin infections
 - History of gestational diabetes (every 2 years)
 - FH of diabetes - parent, sibling (every 2 years)
 - If taking drugs that can cause high blood glucose (corticosteroids >1m, ARVs, antipsychotics)
 - TB

Diagnosis	Symptoms	Associated Complications
<p>If symptomatic: One abnormal result – HbA1c >6.5 OR Fasting Sugar >7</p> <p>If asymptomatic: Two abnormal results at two different times - HbA1c >6.5 OR Fasting sugar >7</p>	<ul style="list-style-type: none"> • Polydipsia • Polyuria • Weight loss • Recurrent infections • Lethargy 	<ul style="list-style-type: none"> • Hyperglycaemia • Hypoglycaemia (due to medication) • Cardiovascular disease • Foot disease • Renal Failure • Retinopathy • Peripheral Neuropathy • Autonomic neuropathy • Erectile dysfunction • Infection • Depression • Complications of pregnancy

Management

- Patient education** – begin at diagnosis then continue throughout; involve patient and check understanding
 - **lifestyle modification** (diet, weight, exercise, smoking); nutritionist
 - information about the disease and management
 - danger signs (see box)
- Blood sugar control** – see chart below
- Cardiovascular risk management**
 - **Manage hypertension** as per hypertension guideline (use ACEI/ARB if possible; target <140/90, or <130/80 if proteinuria)
 - Do not *routinely* start statin, but give to all with known CVD
 - Aspirin *only for secondary prevention* of CVD
- Prevention, detection and treatment of complications**
 - Start all patients with evidence of renal failure/nephropathy on an ACEI/ARB (see CKD guideline)
 - Check feet at every visit
 - Discuss contraception with women of reproductive age; need for folic acid 5mg OD if could become pregnant

Danger signs

If patient experiences any of the below, they should seek immediate care:


- Drowsiness
- Change in level of consciousness/collapse
- Feeling dizzy or weak
- Rapid breathing
- Weight loss
- Blurred vision
- Concern regarding the patient's health

Investigations

	At diagnosis	Frequency of testing after diagnosis
HbA1c	✓	Every 2-3 months until controlled, then 6 monthly
FBS	x	Can be used as alternative if HbA1c is not available or if information required before next HbA1c is due
RBS	x	No benefit for routine check unless concerns a patient is acutely unwell
Urinalysis (dipstick)	✓	Annually – looking for significant proteinuria
Creatinine	✓	Annually
Retinal screening	✓	Annually
Feet examination	✓	At each clinical visit
Dental	✓	Annually
TB screening	✓	At each clinical visit
Lipids	x	No real benefit in checking levels

Protocol for control of blood glucose in Type 2 diabetes

NO NEED TO ROUTINELY CHECK RBS!!
BUT if an RBS is taken and found to be very high **only take action if patient is unwell**, otherwise check HbA1c and follow this protocol
NO NEED TO START INSULIN ROUTINELY IF HBA1C IS VERY HIGH – follow this protocol



¹ DO NOT use metformin if eGFR<30, caution if eGFR 30-40 (see details in table below)

Prescribing information

Drug	Starting dose	Maximum dose	Additional advice
Metformin	500mg OD, increase to 500mg BD after one week	2.5g daily	<ul style="list-style-type: none"> • Increase gradually to avoid side effects • Aim to reach 1500-2500mg if tolerated • DO NOT use if eGFR<30; use with caution if eGFR 30-45; discuss with consultant • Caution in conditions that can cause tissue hypoxia; stop if dehydration • Main side effects: nausea, diarrhoea • Can try Metformin XR if significant side effects (but more expensive)
Gliclazide	40-80mg OD	320mg daily	<ul style="list-style-type: none"> • Doses >160mg daily split to BD • Risk of hypoglycaemia
Glibenclamide	2.5-5mg OD	15mg daily (10mg am, 5mg noon)	<ul style="list-style-type: none"> • Only use if gliclazide not available as higher risk of hypoglycaemia • Care in elderly – start lower dose
Insulin (Glargine)	Commence at 0.1 units/kg/day given once daily at bedtime	Adjust dose by around 10% once or twice a week until the morning FBS <9	<ul style="list-style-type: none"> • Always discuss with consultant before starting insulin • Use once daily Glargine if available in preference to Mixtard (similar price in the long run, only once daily injections and lower risk of hypoglycaemia) • Needs significant patient education including training on self-testing, injection technique and hypoglycaemia recognition and management
Insulin (Mixtard)	Commence at 0.2 units/kg/day total dose Give 2/3 dose with breakfast and 1/3 dose with evening meal	Adjust dose by around 10% once or twice a week until the FBS <9 on waking and before evening meal	
Newer diabetic drugs (pioglitazone, gliptins, gliflozins...)	<p>Do not routinely use the newer diabetic drugs. In most cases the above drugs are the most effective options.</p> <p>If specific reasons to consider an alternative medication, please discuss with a consultant first</p>		

Consultant review if any of the following:

- Any patient with Type 1 diabetes
- Systemically unwell
- Concerns regarding HHS or DKA
- Renal impairment
- Previous episodes of hypoglycaemia
- Struggling to get glycaemic control
- Concurrent HIV
- Considering newer drugs

References:

Noncommunicable Diseases (NCD) Country Profiles, WHO, 2014.

http://guidelines.health.go.ke:8000/media/Kenya_National_Diabetes_Strategy.pdf

<https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-pdf-1837338615493>

2019 Clinical Guide Primary Care International (adapted for this context and location. PCI have not been involved in, nor hold responsibility for any adaptations. Original can be found at: <https://ncd-training.org/open-source-clinical-guide/>

BMJ 2019;367:l5887 <https://www.bmj.com/content/367/bmj.l5887>